The global amyotrophic lateral sclerosis treatment market size reached USD 787.0 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,134.5 Million by 2033, exhibiting a growth rate (CAGR) of 4.15% during 2025-2033.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 787.0 Million |
Market Forecast in 2033
|
USD 1,134.5 Million |
Market Growth Rate 2025-2033 | 4.15% |
Amyotrophic Lateral Sclerosis (ALS) Treatment refers to a degenerative disease that affects the nerve cells in the spinal cord and brain, resulting in loss of muscle control. It primarily occurs due to gene mutation, disorganized immune response, chemical imbalance, etc. Some of the common symptoms of ALS include muscle stiffness, twitching of the muscles, weakness in the legs or arms, cognitive and behavioral changes, trouble in swallowing, slurred speech, etc. The diagnosis of ALS relies on medical history, physical examination, electrodiagnostic testing, and neuroimaging.
The rising incidences of neurodegenerative disorders due to changing lifestyle patterns and hectic schedules of the individuals are primarily driving the Amyotrophic Lateral Sclerosis Treatment treatment market. Besides this, the expanding geriatric population, who are more susceptible to such neurological ailments, is also augmenting the market growth. Furthermore, several NGOs and private organizations are undertaking numerous initiatives to increase awareness regarding the diagnosis and treatment of ALS among the masses. This, in turn, is creating a positive outlook for the market. Additionally, the growing penetration of targeted and symptomatic treatment options for ALS is acting as a significant growth-inducing factor. Moreover, the elevating focus on clinical trials and faster approval of oral drugs for ALS treatment is also bolstering the market growth. Moreover, the increasing strategic collaborations among various research institutes to develop innovative treatment procedures that aim at enhancing muscle function, immune modulation, and neuroprotection are further catalyzing the global market. In the coming years, the continuous upgradation of healthcare infrastructures along with elevating penetration of refurbishment policies will continue to drive the global amyotrophic lateral sclerosis (ALS) treatment market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global amyotrophic lateral sclerosis treatment market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on ALS type, drug type, diagnosis type, treatment and distribution channel.
Breakup by ALS Type:
Breakup by Drug Type:
Breakup by Diagnosis Type:
Breakup by Treatment:
Breakup by Distribution Channel:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being AB Science, Ascend Pharmaceuticals LLC, BrainStorm Cell Therapeutics Inc., Corestem Inc., Cytokinetics Inc., Eledon Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., ITF Pharma (Italfarmaco S.p.A), Mitsubishi Chemical Group Corpotion, Revalesio Corporation and Treeway B.V.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Million USD |
Segment Coverage | ALS Type, Drug Type, Diagnosis Type, Treatment, Distribution Channel, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | AB Science, Ascend Pharmaceuticals LLC, BrainStorm Cell Therapeutics Inc., Corestem Inc., Cytokinetics Inc., Eledon Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., ITF Pharma (Italfarmaco S.p.A), Mitsubishi Chemical Group Corpotion, Revalesio Corporation and Treeway B.V. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global amyotrophic lateral sclerosis treatment market was valued at USD 787.0 Million in 2024.
We expect the global amyotrophic lateral sclerosis treatment market to exhibit a CAGR of 4.15% during 2025-2033.
The rising incidences of neurodegenerative disorders, along with the increasing awareness towards the diagnosis and treatment of ALS based on medical history, physical examination, electrodiagnostic testing, and neuroimaging of the masses, are primarily driving the global amyotrophic lateral sclerosis treatment market.
The sudden outbreak of the COVID-19 pandemic had led to postponement of elective amyotrophic lateral sclerosis treatments to reduce the risk of the coronavirus infection upon hospital visits or interaction with healthcare professionals or medical equipment.
Based on the treatment, the global amyotrophic lateral sclerosis treatment market has been segmented into medication, stem cell therapy, and others. Currently, medication holds the majority of the total market share.
Based on the distribution channel, the global amyotrophic lateral sclerosis treatment market can be divided into hospital pharmacies, retail pharmacies, and others. Among these, hospital pharmacies exhibit a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global amyotrophic lateral sclerosis treatment market include AB Science, Ascend Pharmaceuticals LLC, BrainStorm Cell Therapeutics Inc., Corestem Inc., Cytokinetics Inc., Eledon Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., ITF Pharma (Italfarmaco S.p.A), Mitsubishi Chemical Group Corpotion, Revalesio Corporation, and Treeway B.V.